Today: October 1, 2016, 2:10 pm

Global anti-cancer agents market: Afinitor from Novartis a key drug in the short term
Leading Anti-Cancer Drugs and Associated Market 2013-2023 - a new market research report on 2014-03-14 17:00:05
Do you want to assess the future of cancer medicines? Our updated report gives you revenue predictions there from 2013, helping you stay ahead. You find financial data, R&D trends, opportunities, and outlooks.

In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected drugs.

You see what shapes that industry and find its revenue prospects

Discover, then, what the future holds for anti-cancer products. Read on to explore that industry and see what its future market could be worth.

Forecasts to 2023 and other analyses show you commercial potentials

Besides revenue forecasting to 2023, you find historical data, growth rates, and market shares. You assess quantitative and qualitative analysis, business news, outlooks, and developments (R&D). You also gain 114 tables, 47 charts, and three interviews.

Is finding data for cancer treatment a challenge? Our work lets you investigate the most promising and lucrative parts of applied oncology, helping you stay ahead in knowledge. That way, you reduce your risk of missing out. Finding data you need has just got easier.

Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses, and decisions there.

The following sections show, then, how you benefit from our new investigation and analysis.

Discover outlooks for the world market and submarkets

Along with prediction of overall world market value to 2023, our report shows you revenue forecasting of four submarkets at world level:

• Immunotherapies
• Targeted therapies
• Hormone-based agents
• Chemotherapies.

Also our study discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your business to develop. Assess leading brands too.

See forecasts for the leading 25 cancer-treating drugs

How will leading drugs perform to 2023 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:

• Rituxan
• Herceptin
• Avastin
• Gleevec
• Revlimid
• Alimta
• Velcade.

There you discover how high sales can go, to 2023, finding drugs and years with highest predicted growth and revenues. You see what´s happening, then, understanding trends, competition, challenges, and opportunities. Also, assess drugs approved from 2012 to 2013.

You find geographical revenue predictions too.

Leading national markets - where lie highest revenues and growth?

Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharma companies will occur from 2013. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

• US
• Japan
• Germany, France, UK, Italy, and Spain (EU5)
• Brazil, Russia, India, and China (BRIC).

You find potential. Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change medical prescribing and the commercial landscape.

Research and development - assess innovation, trends, and possibilities

What´s happening in oncological R&D? You see trends for treating these cancers:

• Bladder
• Brain
• Breast
• Cervix
• Gut
• Kidney
• Leukaemia
• Liver
• Lung.

Our study also discusses products in development for these cancers:

• Lymphoma
• Multiple myeloma
• Ovary
• Pancreas
• Prostate
• Sarcoma and skin
• Stomach
• Other cancers.

R&D in oncology holds strength, variety, and promise. You assess innovations, hearing about developments and finding their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing issues to help your work. Also, see what shapes the market from 2013.

What affects the industry and market for anti-cancer drugs?

Our report discusses issues and events affecting that industry and market from 2013, including these:

• Epidemiology - incidence, prevalence, mortality, and survival
• Tumour (tumor) resistance, heterogeneity, and other medical challenges
• Personalised medicine, live licensing, and theranostics
• Cost-effectiveness, pricing, and reimbursement
• Payers and healthcare policy.

The study also discusses other aspects of cancer treatment, including these:

• Monoclonal antibodies (mAbs), cancer vaccines, and other technologies
• Efficacy, toxicity, and alternative treatments
• Biosimilars (follow-on-protein products) and generics
• Pharmacogenomics and genome screening
• Biomarkers and diagnostics.

That way, you explore technological, economic, social, and political (STEP) questions, assessing outlooks for the business. You also analyse the anti-cancer drug industry´s strengths, weaknesses, opportunities, and threats (SWOT).

See, then, what the future holds.

Leading companies in cancer treatment and 2017 market value

From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-cancer agents will reach $116.5bn in 2017, and expand further to 2023.

Our analyses show you what technologies, products, and organisations hold greatest potential. They cover these leading companies, among others:

• Roche
• Novartis
• Celgene
• AstraZeneca
• Eli Lilly
• Merck & Co.

Prospects for R&D in oncology are strong, and from 2013 there will arise many opportunities. Our work shows you possibilities, helping you stay ahead.

Nine ways Leading Anti-Cancer Drugs and Associated Market 2013-2023 helps you

In particular, then, our investigation gives you the following knowledge:

• Revenue to 2023 for the world anti-cancer drugs market - discover that industry´s overall sales potential
• Revenues to 2023 for 4 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues
• Revenues to 2023 for 25 leading products - find sales outlooks for top brands, seeing how they can compete and succeed
• Forecasts to 2023 for 11 leading national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth
• Assessments of leading companies - hear about participants´ activities, capabilities, results, and outlooks
• Review of R&D in oncology - explore progress in research and development, finding technological and clinical possibilities
• Interviews with authorities in the field - discover debates and opinions to help you stay ahead
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages
• Competition and opportunities - investigate what shapes that market´s future, including ways to develop business.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 1173 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.